Managing Side Effects of Cancer Cachexia Treatments: What Patients Need to Know
Cancer Cachexia Treatment Development Status
Cancer cachexia is a severe condition causing muscle loss and weight reduction in cancer patients. Recent research has proposed new treatments linked to gut microbiota, with KAIST and KIST successfully developing cachexia therapies. Notably, strategies focusing on regulating gut bacteria have gained attention.
Current Research Trends
MetaPharm's 'ASCA101CC' received domestic Phase 2 clinical trial approval, while Pfizer's GDF-15 antibody candidate 'Ponsegromab' recorded an average 5.6% weight increase in Phase 2 trials. Anamorelin was the first treatment to prove efficacy in improving cachexia symptoms, contributing to better quality of life (QOL) for patients.
GC Green Cross Wellbeing planned a technology export deal for cancer cachexia treatments in 2021, which led to stock price increases. A muscle regeneration protein discovered in Antarctic fish has introduced new possibilities for cachexia treatment.
Research Development and Clinical Results
KAIST found a breakthrough in cachexia treatment on August 2, 2026, while KIST presented a strategy using gut microbiota regulation on August 14 of the same year. Donga Ilbo and v.daum.net reported on the connection between cancer cachexia and gut microbiota on August 16, 2026.
Korea Biomedical Institute announced steady progress in new drug development for cancer cachexia on December 18, 2025, which is expected to improve survival rates and expand treatment options. MetaPharm's 'ASCA101CC' received Phase 2 IND approval on January 7, 2025.
Pfizer's 'Ponsegromab' recorded a 5.6% average weight gain in Phase 2 trials on September 19, 2024, while Anamorelin first demonstrated efficacy for cachexia symptoms on October 2, 2014.

Treatment Approaches and Guidelines
Cancer cachexia treatment guidelines recommend enteral nutrition combined with drug intervention. Some misinformation suggests avoiding meat consumption; however, accurate nutritional management is emphasized as essential.
Research Status and Development Outlook
Diverse companies and research institutions are actively developing cancer cachexia treatments. KAIST and KIST have proposed strategies based on regulating gut microbiota, while MetaPharm and GC Green Cross Wellbeing focus on clinical development.
The muscle regeneration protein discovered in Antarctic fish has introduced a new direction for cachexia treatment, with ongoing research exploring its connection to gut microbiota. Anamorelin is the representative treatment whose quality-of-life improvement effects have been proven.
Cause Investigation and Diagnosis Criteria
Cancer cachexia causes severe muscle loss and weight reduction in cancer patients, threatening survival rates. It is linked to imbalances in gut microbiota, with research highlighting gut regulation as a key treatment factor.
Diagnosis of cachexia is based on weight loss and muscle reduction; treatment combines drug intervention with nutritional management. Recent studies have highlighted the importance of regulating gut microbiota for effective therapy.
Response Strategies and Safety Information
Cancer cachexia patients can manage symptoms through enteral nutrition and drug intervention. Misinformation about avoiding meat consumption does not exist; accurate nutritional care is essential for treatment.
MetaPharm's 'ASCA101CC' received Phase 2 approval on January 7, 2025, while Pfizer's 'Ponsegromab' demonstrated weight gain in Phase 2 trials on September 19, 2024. These developments are expected to expand cachexia treatment options.
Verified Information
Ongoing research continues in cancer cachexia treatments, particularly focusing on gut microbiota regulation as a new therapeutic strategy. Anamorelin's effectiveness and GC Green Cross Wellbeing's technology export plans have been confirmed.
A study on the muscle regeneration protein discovered in Antarctic fish was reported by Joongang Ilbo on July 21, 2026, introducing new possibilities for cachexia treatment.
Frequently Asked Questions
How has the effectiveness of cancer cachexia treatments been proven?
MetaPharm's 'ASCA101CC' received domestic Phase 2 clinical trial approval, while Pfizer's 'Ponsegromab' recorded an average 5.6% weight increase in Phase 2 trials.
What role does gut microbiota regulation play in cancer cachexia treatment?
Gut microbiota imbalance is linked to cachexia, with KIST and KAIST research identifying its regulation as a key factor in treatment strategies.
What are the effects of Anamorelin?
Anamorelin was the first treatment to prove efficacy in improving cachexia symptoms, contributing to better quality of life (QOL) for patients.
Frequently Asked Questions
Cancer cachexia is a serious condition affecting cancer patients. Recent research has proposed new treatments related to gut microbiota, with KAIST and KIST providing new directions in treatment approaches. MetaPharm and GC Green Cross Wellbeing's clinical development efforts are expected to improve survival rates and expand treatment options.
The discovery of muscle regeneration proteins in Antarctic fish introduces new possibilities for cachexia treatment, while Anamorelin has proven quality-of-life improvements. Research into gut microbiota regulation will continue as a key focus area for future treatments.
View all related articles on this topic in one place.
View Related ArticlesFAQ
How has the effectiveness of cancer cachexia treatments been proven?
MetaPharm's 'ASCA101CC' received domestic Phase 2 clinical trial approval, while Pfizer's 'Ponsegromab' recorded an average 5.6% weight increase in Phase 2 trials.
What role does gut microbiota regulation play in cancer cachexia treatment?
Gut microbiota imbalance is linked to cachexia, with KIST and KAIST research identifying its regulation as a key factor in treatment strategies.
What are the effects of Anamorelin?
Anamorelin was the first treatment to prove efficacy in improving cachexia symptoms, contributing to better quality of life (QOL) for patients.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 악액질 치료제 복용 시 나타나는 부작용과 대처법